Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Heterogeneity of treatment effect
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Heterogeneity of treatment effect

1 evidence topic · 1 source

IMPALA-2 treatment effect across baseline DLCO subgroups

“For DLCO%, the magnitude of the treatment effect was similar across DLco% subgroups at 24 and 48 weeks” (opens the source at this quote in a new tab)